Creative Planning lifted its stake in shares of Teladoc Health Inc (NYSE:TDOC) by 27.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,772 shares of the health services provider’s stock after acquiring an additional 1,667 shares during the period. Creative Planning’s holdings in Teladoc Health were worth $432,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc boosted its stake in Teladoc Health by 26.9% in the 3rd quarter. Vanguard Group Inc now owns 5,874,182 shares of the health services provider’s stock worth $507,236,000 after buying an additional 1,244,388 shares during the last quarter. Riverbridge Partners LLC boosted its stake in Teladoc Health by 24.0% in the 1st quarter. Riverbridge Partners LLC now owns 1,523,561 shares of the health services provider’s stock worth $84,710,000 after buying an additional 294,523 shares during the last quarter. Macquarie Group Ltd. boosted its stake in Teladoc Health by 101.5% in the 4th quarter. Macquarie Group Ltd. now owns 1,125,275 shares of the health services provider’s stock worth $55,780,000 after buying an additional 566,839 shares during the last quarter. Bellevue Group AG boosted its stake in Teladoc Health by 83.1% in the 4th quarter. Bellevue Group AG now owns 1,073,839 shares of the health services provider’s stock worth $53,230,000 after buying an additional 487,319 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Teladoc Health by 86.5% in the 4th quarter. Bank of New York Mellon Corp now owns 980,577 shares of the health services provider’s stock worth $48,605,000 after buying an additional 454,702 shares during the last quarter.
A number of equities analysts have recently commented on the company. Robert W. Baird upgraded Teladoc Health from a “neutral” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Monday, January 14th. They noted that the move was a valuation call. Berenberg Bank assumed coverage on Teladoc Health in a report on Thursday, January 31st. They issued a “buy” rating and a $80.00 price objective on the stock. Cantor Fitzgerald restated a “hold” rating and issued a $70.00 price objective (down from $83.00) on shares of Teladoc Health in a report on Wednesday, February 27th. Zacks Investment Research upgraded Teladoc Health from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Finally, SunTrust Banks raised their price objective on Teladoc Health to $75.00 and gave the stock a “positive” rating in a report on Monday, March 4th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $81.00.
Shares of NYSE:TDOC opened at $61.56 on Thursday. The stock has a market cap of $4.44 billion, a P/E ratio of -42.75 and a beta of 1.38. The company has a current ratio of 7.54, a quick ratio of 7.54 and a debt-to-equity ratio of 0.42. Teladoc Health Inc has a one year low of $42.08 and a one year high of $89.05.
Teladoc Health (NYSE:TDOC) last announced its earnings results on Wednesday, February 27th. The health services provider reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $122.74 million for the quarter, compared to the consensus estimate of $120.19 million. Teladoc Health had a negative return on equity of 10.86% and a negative net margin of 22.63%. On average, equities analysts forecast that Teladoc Health Inc will post -1.53 earnings per share for the current year.
In related news, insider Adam C. Vandervoort sold 5,550 shares of the firm’s stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $61.69, for a total transaction of $342,379.50. Following the sale, the insider now directly owns 2,934 shares in the company, valued at approximately $180,998.46. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Lewis Levy sold 1,285 shares of the firm’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $67.21, for a total value of $86,364.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 185,840 shares of company stock worth $11,242,619. Company insiders own 3.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Equities Focus and is owned by of Equities Focus. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.equitiesfocus.com/2019/05/09/creative-planning-has-432000-position-in-teladoc-health-inc-tdoc.html.
Teladoc Health Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Article: Calculating net profit and net profit margin ratio
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.